[1] BELLOU E, BAKER E, LEONENKO G, et al. Age-dependent effect of APOE and polygenic component on Alzheimer’s disease[J]. Neurobiol Aging,2020,93(1):69-77. [2] GUO J X, WANG Z Y, LIU R S, et al. Memantine, donepezil, or combination therapy—what is the best therapy for Alzheimer’s disease? A network meta-analysis[J]. Brain Behav,2020,1(1): e1831-e1844. [3] YU X Y, YU W H, YANG W K, et al. Usage and adherence of antidementia drugs in a memory clinic cohort in Chongqing, Southwest China[J]. Psychogeriatrics,2020,20(5):706-712. [4] MCKHANN G M, KNOPMAN D S, CHERTKOW H, et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the national institute on aging-Alzheimer’s association workgroups on diagnostic guidelines for Alzheimer’s disease[J]. Alzheimer’s Dement, 2011, 7(3): 263-269. [5] KARVE S, CLEVES M A, HELM M, et al. Good and poor adherence: optimal cut-point for adherence measures using administrative claims data[J]. Curr Med Res Opin,2009,25(9):2303-2310. [6] PUDELEWICZ A, TALARSKA D, BACZYK G. Burden of caregivers of patients with Alzheimer’s disease[J]. Scand J Caring Sci,2018,33(2):336-341. [7] BHATTACHARJEE S, PATANWALA A E, LOCIGANIC W H, et al. Alzheimer’s disease medication and risk of all-cause mortality and all-cause hospitalization: a retrospective cohort study[J]. Alzheimer’s Dement,2019,5(1):294-302. [8] KU L E, LI C, SUN Y. Can persistence with cholinesterase inhibitor treatment lower mortality and health-care costs among patients with Alzheimer’s disease? A population-based study in Taiwan[J]. Am J Alzheimer’s Dis,2017,33(2):86-92. [9] RIEPE M, WEINMAN J, OSAE J, et al. Factors associated with greater adherence to and satisfaction with transdermal rivastigmine in patients with Alzheimer’s disease and their caregivers[J]. Dement Geriatr Cogn,2015,40(1/2):107-119. [10] TU Q, ZOU Y, ZHANG M, et al. Application status of memantine in patients with dementia in the Chongqing area of Southwest China[J]. J Clin Geriatr,2015,6(3):85-88. [11] DHILAV V, SINGH P, ANANG K S. Medication adherence survey of drugs useful in prevention of dementia of Alzheimer’s type among Indian patients[J]. Int Psychogeriatr,2013,25(9):1409-1413. [12] YANG H F, CONG J Y, ZANG X Y, et al. A study on knowledge, attitudes and health behaviours regarding Alzheimer’s disease among community residents in Tianjin, China[J]. J Psychiatr Ment Health Nurs,2015,22(9):706-714. [13] HALLIKAINEN I, KOIVISTO A M, VALIMAKI T. The influence of the individual neuropsychiatric symptoms of people with Alzheimer disease on family caregiver distress-a longitudinal study[J]. Int J Geriatr Psych,2018,33(9):1207-1212. [14] KONGPAKWATTANA K, DILOKTHORASAKUL P, DEITHEVAPORN C, et al. Compliance and persistence with Alzheimer’s disease treatment: a retrospective analysis of multiregional hospital databases in Thailand[J]. J Med Econ,2019,22(1):26-34. |